M
Michel Tulliez
Researcher at French Institute of Health and Medical Research
Publications - 38
Citations - 2042
Michel Tulliez is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Imatinib mesylate & Nilotinib. The author has an hindex of 18, co-authored 38 publications receiving 1819 citations.
Papers
More filters
Journal ArticleDOI
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot,Aude Charbonnier,Pascale Cony-Makhoul,Philippe Agape,Franck E. Nicolini,Bruno Varet,Martine Gardembas,Gabriel Etienne,Delphine Rea,Lydia Roy,Martine Escoffre-Barbe,Agnès Guerci-Bresler,Michel Tulliez,Stéphane Prost,Marc Spentchian,Jean Michel Cayuela,Josy Reiffers,Jean-Claude Chomel,Ali G. Turhan,Joelle Guilhot,François Guilhot,Francois-Xavier Mahon +21 more
TL;DR: Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR, and should be a criterion for resuming therapy.
Journal ArticleDOI
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne,Joelle Guilhot,Delphine Rea,Françoise Rigal-Huguet,Franck E. Nicolini,Aude Charbonnier,Agnès Guerci-Bresler,Laurence Legros,Bruno Varet,Martine Gardembas,Viviane Dubruille,Michel Tulliez,Marie-Pierre Noel,Jean-Christophe Ianotto,Bruno Villemagne,Martin Carre,François Guilhot,Philippe Rousselot,Francois-Xavier Mahon +18 more
TL;DR: With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular response with no late MR.
Journal ArticleDOI
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea,Franck E. Nicolini,Michel Tulliez,François Guilhot,Joelle Guilhot,Agnès Guerci-Bresler,Martine Gardembas,Valérie Coiteux,Gaelle Guillerm,Laurence Legros,Gabriel Etienne,Jean-Michel Pignon,Bruno Villemagne,Martine Escoffre-Barbe,Jean-Christophe Ianotto,Aude Charbonnier,Hyacinthe Johnson-Ansah,Marie-Pierre Noel,Philippe Rousselot,Francois-Xavier Mahon +19 more
TL;DR: In conclusion, discontinuation of first-line or subsequent 2G-TKI yields promising TFR rates without safety concerns and a landmark analysis demonstrated that loss of MR4.5 3 months after stopping TKI was predictive of failure to maintain MMR later on.
Journal ArticleDOI
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients
Laurence Valeyrie,Sylvie Bastuji-Garin,Jean Revuz,Nicolas Bachot,Janine Wechsler,Patrice Berthaud,Michel Tulliez,Stéphane Giraudier +7 more
TL;DR: Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent.
Journal ArticleDOI
A new c-kit mutation in a case of aggressive mast cell disease.
Jean-Michel Pignon,Stéphane Giraudier,Phillippe Duquesnoy,Hélène Jouault,Michèle Imbert,William Vainchenker,Jean-Paul Vernant,Michel Tulliez +7 more
TL;DR: Molecular studies of mast cell DNA and RNA revealed a new c‐kit heterozygous mutation that leads to a drastic amino‐acid change and is located close to the highly oncogenic Asp816Val, suggesting that the Asp820Gly has a potential role in c‐Kit activation.